Colin Pritchard
Molecular Genetic Pathology · Seattle, WANPI 1457550022
Payments from drug & device makers
$652,771in general payments, 2019–2025
Across 7 payments — averaging $93,253 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Foundation Medicine, Inc.$602K
- Novo Nordisk US Research & Development, Inc.$44K
- Astrazeneca UK Limited$7K
What the payments were for
- Consulting fees$6,655100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Foundation Medicine, Inc. | 4 | $602,100 |
| Novo Nordisk US Research & Development, Inc. | 2 | $44,016 |
| Astrazeneca UK Limited | 1 | $6,655 |
How this compares
Too few molecular genetic pathology providers in Washingtonto place this figure against a meaningful peer group, so we don't.
Other molecular genetic pathology in Seattle
- Eric KonnickSeattle$27K
- Sean KeenanSeattle$15
- Charles SaileyVancouver$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.